Treatment of metastatic breast cancer with π‘›π‘Žπ‘-paclitaxel in the community practice setting: a US Oncology survey.

@article{Patt2015TreatmentOM,
  title={Treatment of metastatic breast cancer with π‘›π‘Žπ‘-paclitaxel in the community practice setting: a US Oncology survey.},
  author={Debra A Patt and Debra Rembert and Deyanira Corzo},
  journal={The Journal of community and supportive oncology},
  year={2015},
  volume={13 5},
  pages={173-80}
}
BACKGROUND Different dosages-schedules of nab-paclitaxel have been assessed in trials of metastatic breast cancer (MBC). However, there is limited information on nab-paclitaxel dosing-scheduling in the community setting. OBJECTIVE To report on experience with nab-paclitaxel for human epidermal growth factor receptor 2 (HER2)-negative MBC and identify patient characteristics affecting nab-paclitaxel treatment patterns in the community practice setting. METHODS From September 6-October 21… CONTINUE READING